Elderly Patients with Rectal Cancer May Face Similar Survival Outcomes as Younger Patients
Older patients seem to face similar outcomes as younger patients when treated with neoadjuvant chemoradiation for rectal cancer.
Older patients seem to face similar outcomes as younger patients when treated with neoadjuvant chemoradiation for rectal cancer.
Standard combined modality treatment for locally advanced rectal cancer had less disease-free survival than a new CRO/ARO/AIO-04 regimen.
Cumulative exposure to statins after a diagnosis of colorectal cancer was associated with lower overall mortality.
Single nucleotide polymorphism in the let-7 complementary site 6 of KRAS mRNA may be a response biomarker in colorectal cancer.
Investigators recommend prioritized screening in certain pockets of the U.S. that are statistically identified as colorectal cancer (CRC) death hotspots.
Greater progress in reducing colorectal cancer incidence, mortality rates observed in Northeastern states compared to Southern states.
Patients with colorectal cancer who have the variant rs9929218 at 16q22 are at an increased risk for worse survival.
High-dose chemoradiotherapy and watchful waiting might be safe alternative to abdominoperineal resection for treatment of rectal cancer.
mFOLFOX6 administered concurrently with radiation therapy resulted in a higher pathological complete response in rectal cancer.
A recent letter in JCO discusses whether patients with locally advanced rectal cancer need adjuvant chemotherapy.